Holen Sie sich die Stockscreener-App
63.81
3.72%
2.4539
Schlusskurs vom Vortag:
$61.36
Offen:
$61.98
24-Stunden-Volumen:
709.01K
Relative Volume:
1.00
Marktkapitalisierung:
$2.40B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-91.00M
KGV:
-17.39
EPS:
-3.67
Netto-Cashflow:
$-74.38M
1W Leistung:
+13.75%
1M Leistung:
-16.62%
6M Leistung:
+5.46%
1J Leistung:
+16.72%
1-Tages-Spanne:
$61.55
$64.16
1-Wochen-Bereich:
$55.51
$67.27
52-Wochen-Spanne:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Firmenname
Disc Medicine Inc
Sektor
Branche
Telefon
(617) 674-9274
Adresse
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
63.69 | 2.32B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.83 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.15 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.69 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.96 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-11 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-02-27 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-01 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-17 | Eingeleitet | Raymond James | Outperform |
| 2023-04-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Eingeleitet | Stifel | Buy |
| 2023-04-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-03-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Disc Medicine Inc Aktie (IRON) Neueste Nachrichten
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route - AOL.com
HC Wainwright Reduces Earnings Estimates for Disc Medicine - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Insider Selling: Disc Medicine (NASDAQ:IRON) CFO Sells $256,154.50 in Stock - MarketBeat
Jean Franchi Sells 7,081 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine: Downgrading As CRL Puts APOLLO Study Into Question (NASDAQ:IRON) - Seeking Alpha
HC Wainwright Predicts Weaker Earnings for Disc Medicine - MarketBeat
Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program - Yahoo Finance
Disc Medicine (IRON) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod - WNWN-FM
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
Disc Medicine (NASDAQ:IRON) Insider William Jacob Savage Sells 3,256 Shares - MarketBeat
Disc Medicine (NASDAQ:IRON) COO Sells $203,100.66 in Stock - MarketBeat
Disc Medicine (NASDAQ:IRON) CEO John Quisel Sells 13,264 Shares - MarketBeat
Insider Selling: Disc Medicine (NASDAQ:IRON) Insider Sells 2,853 Shares of Stock - MarketBeat
Khara, Disc Medicine chief legal officer, sells $179k in shares - Investing.com India
Khara, Disc Medicine chief legal officer, sells $179k in shares By Investing.com - Investing.com Canada
Disc Medicine CCO Stephenson sells $347k in shares By Investing.com - Investing.com Canada
Disc Medicine chief medical officer sells $204,672 in stock By Investing.com - Investing.com South Africa
Disc Medicine CCO Stephenson sells $347k in shares - Investing.com
Disc Medicine CEO Quisel sells $833k in shares By Investing.com - Investing.com Canada
Disc Medicine (NASDAQ:IRON) Drives Biotechnology Shifts In Views On Development Strategy - Kalkine Media
Disc Medicine Faces Turbulence as FDA Raises Concerns on Drug Approval - timothysykes.com
Disc Medicine (NASDAQ:IRON) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Stifel cuts Disc Medicine stock price target on FDA setback By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts Disc Medicine stock price target on FDA setback - Investing.com Canada
IRON: Stifel Lowers Price Target to $110, Maintains Buy Rating | - GuruFocus
Disc Medicine’s Stock Dips as FDA Approves Pending Concerns - StocksToTrade
Disc Medicine Plans FDA Response on Bitopertin With Phase 3 Results; Shares Rise - marketscreener.com
Disc Medicine stock slumps after FDA declines approval for inherited disorder drug over efficacy concerns - MSN
Disc Medicine Faces Turmoil Amid FDA Concerns but Investors Not Losing Hope - timothysykes.com
Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says - marketscreener.com
Wedbush Adjusts Price Target on Disc Medicine to $88 From $110, Maintains Outperform Rating - marketscreener.com
Disc Medicine After The CRL: Risk Now Rests On APOLLO (NASDAQ:IRON) - Seeking Alpha
Wedbush Issues Pessimistic Forecast for Disc Medicine (NASDAQ:IRON) Stock Price - MarketBeat
BMO Capital Markets Issues Pessimistic Forecast for Disc Medicine (NASDAQ:IRON) Stock Price - MarketBeat
Disc Medicine, Inc. (IRON) Stock Report: Analyst Consensus Predicts 84.84% Upside Potential - DirectorsTalk Interviews
IRON: Wells Fargo Lowers Price Target Amidst Maintaining Overwei - GuruFocus
Disc Medicine executives noted during a conference call that the policy debate over accelerated approval pathways has spanned multiple government administrations. - Bitget
Disc Medicine Addresses FDA Rejection of Bitopertin Filing - TipRanks
Disc Medicine outlines FDA CRL for bitopertin, aims to complete APOLLO and respond by late 2026 - TradingView
IRON: FDA requests APOLLO study results for bitopertin approval; decision expected by mid-2027 - TradingView
Disc Medicine Shares Drop 22% Due to FDA Regulatory Setback - Intellectia AI
FDA Delays Disc Medicine's Rare Disease Drug - Bitget
What's Going On With Disc Medicine Stock Tuesday?Disc Medicine (NASDAQ:IRON) - Benzinga
Disc Medicine plunges on FDA complete response letter for bitopertin - MSN
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA - MedCity News
Disc Medicine (IRON) Faces Setback After FDA Response - GuruFocus
TimesSquare Capital Management LLC Purchases Shares of 182,170 Disc Medicine, Inc. $IRON - MarketBeat
FDA issues complete response letter to Disc Medicine’s bitopertin NDA - Yahoo Finance
Disc Medicine stock plunges after FDA issues Complete Response Letter By Investing.com - Investing.com Australia
Finanzdaten der Disc Medicine Inc-Aktie (IRON)
Umsatz
Nettogewinn
Free Cashflow
ENV
Disc Medicine Inc-Aktie (IRON) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Franchi Jean M. | Chief Financial Officer |
Feb 17 '26 |
Sale |
62.86 |
4,075 |
256,154 |
78,424 |
0.88%
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):